PA-EXONE
24.6.2020 14:02:10 CEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced the launch of its updated Quick Ship metal 3D printing services, featuring a new digital quoting tool and materials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005137/en/
ExOne Quick Ship will now add the popular stainless steels 316L and 17-4PH to the list of materials offered through instant quoting, with delivery times of 10-15 business days, depending on number of units requested, part size, and other requirements.
“After two years of supplying thousands of 316L and 17-4 parts to select industrial customers, our updated Quick Ship services will now allow any customer to easily acquire and evaluate affordable single-alloy parts 3D printed with binder jetting,” said John Hartner, ExOne CEO.
A new Quick Ship online dashboard, available at www.exone.com/quickship , will allow customers to upload a qualifying digital design file for an instant quote and purchase, as well as create an account to track projects. More than 30 file types are accepted including STL and STP files.
Quick Ship parts will be 3D printed at ExOne’s metal production facility outside Pittsburgh, which has been binder jetting metal parts for more than two decades. It’s home to a fleet of more than two dozen metal 3D printers producing parts for prototype, low-volume, and serial production projects.
Quick Ship Service Represents Critical Progress
Binder jet 3D printing is a method of additive manufacturing in which an industrial printhead deposits a liquid binder onto a thin layer of powdered particles, layer by layer, until an object is formed. Parts printed in metal powders are then sintered in a furnace to fuse the particles.
In development since 1996, ExOne metal binder jet systems are capable of producing parts in more than 20 metals, ceramics and composite materials today. The technology is viewed as a disruptive and sustainable production method, largely because of its high speed, relatively low cost and material flexibility, among other benefits.
“The launch of Quick Ship services for single-alloy metals represents a key step forward in our development of metal binder jetting, and one that signifies our continued confidence in this technology,” said Rick Lucas, ExOne Chief Technology Officer and VP of New Markets. “We also have plans to expand the number of material offerings and size of printable parts in our Quick Ship services by year-end.”
Featured Quick Ship Metal 3D Printers
Quick Ship parts in 316L and 17-4PH will be 3D printed on ExOne’s Innovent+ and X1 25Pro metal 3D printing systems. Both machines feature ExOne’s exclusive Triple ACT system, an advanced compaction technology that delivers industry-leading density and repeatability in metal binder jetting. ExOne 3D printers with Triple ACT are capable of delivering sintered dimensional accuracy of +/- 2.5% on a first print run, with better results possible after additional sintering optimization.
ExOne will continue to offer its popular 316 and 420 materials infiltrated with bronze on its classic M-Flex and R2 metal 3D printing models, which have been in operation since 2013 and 2003, respectively. Infiltrated parts, which offer a variety of functionality and finish benefits, are typically shipped within 10 business days.
Other Materials Available Through Premium Quote
Metal, ceramic and composite materials not available through ExOne’s Quick Ship service will continue to be offered on a limited basis through ExOne’s Premium Quote service. Delivery times will vary based on the project details.
The full list of materials printable on ExOne 3D printing systems can be viewed at www.exone.com/metalmaterial . Materials such as M2 Tool Steel and Inconel 718 are available for quoting, and quote requests may depend on material availability.
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com
or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom